A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

This study tests a combination of three drugs — calaspargase, decitabine, and venetoclax — for children, teenagers, and young adults (up to age 21) with T-cell leukemia or T-cell lymphoblastic lymphoma that has returned or stopped responding to treatment. **You may be eligible if...** - You are aged 1 month to 21 years with relapsed or treatment-resistant T-cell leukemia or T-cell lymphoblastic lymphoma - You have adequate organ function and can swallow tablets - You are at least 30 days past a prior stem cell transplant **You may NOT be eligible if...** - You have another active cancer - You have severe uncontrolled infections or serious heart disease - You have a history of severe allergic reaction to asparaginase - You have a history of pancreatitis (grade 3 or severe anaphylaxis from asparaginase) - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.